Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp’ tech to strengthen its respiratory vaccine pipeline.
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Where Today's News Shapes Tomorrow
